KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Non Operating Investment Income: 2009-2024

Historic Non Operating Investment Income for Ionis Pharmaceuticals (IONS) over the last 13 years, with Dec 2024 value amounting to -$2.9 million.

  • Ionis Pharmaceuticals' Non Operating Investment Income rose 3302.50% to $29.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 1524.07%. This contributed to the annual value of -$2.9 million for FY2024, which is 50.94% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Non Operating Investment Income of -$2.9 million as of FY2024, which was down 50.94% from -$1.9 million recorded in FY2023.
  • Ionis Pharmaceuticals' Non Operating Investment Income's 5-year high stood at $16.5 million during FY2020, with a 5-year trough of -$7.3 million in FY2022.
  • In the last 3 years, Ionis Pharmaceuticals' Non Operating Investment Income had a median value of -$2.9 million in 2024 and averaged -$4.0 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Non Operating Investment Income surged by 8,514.58% in 2020 and then crashed by 172.58% in 2022.
  • Yearly analysis of 5 years shows Ionis Pharmaceuticals' Non Operating Investment Income stood at $16.5 million in 2020, then plummeted by 38.92% to $10.1 million in 2021, then slumped by 172.58% to -$7.3 million in 2022, then skyrocketed by 73.90% to -$1.9 million in 2023, then slumped by 50.94% to -$2.9 million in 2024.